---
title: "INDV: Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294694154.md"
description: "A merger will create a leading CNS biopharma company with a $2.2B portfolio spanning addiction, ADHD, postpartum depression, and Parkinson’s disease. The deal is expected to deliver $125M in annual cost synergies, strong profitability, and significant growth opportunities for shareholders.Original document: Indivior Pharmaceuticals, Inc. [INDV] Slides Release — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-03T12:31:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294694154.md)
  - [en](https://longbridge.com/en/news/294694154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294694154.md)
generator: "portal-rs"
---

# INDV: Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies

A merger will create a leading CNS biopharma company with a $2.2B portfolio spanning addiction, ADHD, postpartum depression, and Parkinson’s disease. The deal is expected to deliver $125M in annual cost synergies, strong profitability, and significant growth opportunities for shareholders.

Original document: Indivior Pharmaceuticals, Inc. \[INDV\] Slides Release — Aug. 3 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [INDV.US](https://longbridge.com/en/quote/INDV.US.md)

## Related News & Research

- [Top Indivior Insider Quietly Ramps Up Stake in Bold New Move](https://longbridge.com/en/news/297262729.md)
- [McKesson to buy Precision Medicine Group in about $2.25 billion deal](https://longbridge.com/en/news/296912806.md)
- [Magnificent 7 Built The AI Boom, 'Munificent Seven' Wants to Power It](https://longbridge.com/en/news/296823523.md)
- [The Best Time to Buy AI? When Everyone’s Afraid of It](https://longbridge.com/en/news/297234851.md)
- [QBIM: Q2 2026 saw 75% revenue growth, higher margins, and strategic product and financing advances](https://longbridge.com/en/news/297274910.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**